Abstract
In this review, we analyzed the status and changes in the research on second-generation (atypical) antipsychotic drugs in the Asia–Pacific region (i.e., Japan, South Korea, Taiwan, Hong Kong, Singapore, and Australia). We also performed a bibliometric study of the literature in this region on atypical antipsychotic drugs (e.g., clozapine, risperidone, olanzapine, ziprasidone, quetiapine, sertindole, aripiprazole, paliperidone, amisulpride, zotepine, asenapine, iloperidone, lurasidone, perospirone, and blonanserin). We applied bibliometric indicators of production and dispersion (i.e., Price's law on the increase of scientific literature and Bradford's law, respectively). We also calculated the participation index of different countries. The data were also correlated with relevant social and health data from the Asia–Pacific region (e.g., the per capita gross domestic product and total per capita expenditure on health and gross domestic expenditure on research and development). All data are discussed together. We also analyzed the different aspects among the six countries in the region.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.